Analysis of the efficacy and safety of a long course of venetoclax in the treatment of patients with acute myeloid leukemia
Objective:To investigate the efficacy and safety of a long course of the venetoclax combination regi-men in the treatment of patients with acute myeloid leukemia(AML),in order to guide a more individualized clini-cal application.Methods:The medical records of AML patients who received a long course of treatment(≥6 cy-cles)with the combination regimen of venetoclax from January 2021 to July 2023 were retrospectively analyzed for the composite complete remission(cCR),progression-free survival(PFS),overall survival(OS),and the occur-rence of adverse events.Results:A total of 27 patients were included with a median follow-up of 15(9.2-17.9)months and a median number of cycles of VEN combination therapy of 8(6-28)cycles.After 2 cycles of treat-ment,24 patients were evaluated for efficacy,with a cCR of 91.67％and a partial remission of 4.17％.The me-dian number of cycles to first cCR for all patients was 1(1-2)cycles,and 55.56％of patients achieved sustained remission.Seventeen patients had minimal residual disease(MRD)results,with a negative conversion rate of 58.82％for MRD.33.33％of patients with sustained negative MRD achieved a durable and deep remission.Among the 27 patients,6 patients(22.22％)had disease progression.The median PFS and OS were not achieved,with a 1-year OS rate of 84.21％.Safety analysis showed that hematologic adverse events were the most common,followed by gastrointestinal symptoms,electrolyte disorders,pulmonary infections,and liver function abnormali-ties.Conclusion:A long course of venetoclax for AML has good efficacy and safety,and some patients can achieve deep and durable remission.Venetoclax can be used as an option for AML patients to consolidate their maintenance therapy.
venetoclaxacute myeloid leukemialong course of treatmentefficacysafety
NETL
NSTL
万方数据
